Xue-Ding Wang

List of Publications by Year
in descending order

48	664	516710	610901
papers	citations	16	24
		h-index	g-index

49	49	49	1086
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Rapid and simultaneous determination of nifedipine and dehydronifedipine in human plasma by liquid chromatography–tandem mass spectrometry: Application to a clinical herb–drug interaction study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 852, 534-544.	2.3	52
2	Combined Detection of NUDT15 Variants Could Highly Predict Thiopurine-induced Leukopenia in Chinese Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2017, 23, 1592-1599.	1.9	48
3	Impact of the haplotypes of the human pregnane X receptor gene on the basal and St John's wort–induced activity of cytochrome P450 3A4 enzyme. British Journal of Clinical Pharmacology, 2009, 67, 255-261.	2.4	41
4	Interactive effects of *CYP3A4, CYP3A5, MDR1* and *NR1I2* polymorphisms on tracrolimus trough concentrations in early postrenal transplant recipients. Pharmacogenomics, 2015, 16, 1355-1365.	1.3	39
5	UPLC–QTOF-MS-Based Plasma Lipidomic Profiling Reveals Biomarkers for Inflammatory Bowel Disease Diagnosis. Journal of Proteome Research, 2020, 19, 600-609.	3.7	39
6	Polymorphisms of ABCG2, ABCB1 and HNF4α are associated with Lamotrigine trough concentrations in epilepsy patients. Drug Metabolism and Pharmacokinetics, 2015, 30, 282-287.	2.2	38
7	Hypoxanthine guanine phosphoribosyltransferase activity is related to 6-thioguanine nucleotide concentrations and thiopurine-induced leukopenia in the treatment of inflammatory bowel disease. Inflammatory Bowel Diseases, 2012, 18, 63-73.	1.9	32
8	Wuzhi Tablet (*Schisandra sphenanthera* Extract) Is a Promising Tacrolimus-Sparing Agent for Renal Transplant Recipients Who Are CYP3A5 Expressers: a Two-Phase Prospective Study. Drug Metabolism and Disposition, 2017, 45, 1114-1119.	3.3	31
9	Simultaneous determination of valproic acid and 2-propyl-4-pentenoic acid for the prediction of clinical adverse effects in Chinese patients with epilepsy. Seizure: the Journal of the British Epilepsy Association, 2012, 21, 110-117.	2.0	27
10	Genetic markers in *CYP2C19* and *CYP2B6* for prediction of cyclophosphamide's 4–hydroxylation, efficacy and side effects in Chinese patients with systemic lupus erythematosus. British Journal of Clinical Pharmacology, 2016, 81, 327-340.	2.4	26
11	Associations of UDP-glucuronosyltransferases polymorphisms with mycophenolate mofetil pharmacokinetics in Chinese renal transplant patients. Acta Pharmacologica Sinica, 2015, 36, 644-650.	6.1	24
12	Association of LEPR and ANKK1 Gene Polymorphisms with Weight Gain in Epilepsy Patients Receiving Valproic Acid. International Journal of Neuropsychopharmacology, 2015, 18, pyv021-pyv021.	2.1	23
13	A Pharmacogenetic Study of Pregnane X Receptor (NR1I2) in Han Chinese. Current Drug Metabolism, 2007, 8, 778-786.	1.2	20
14	Pharmacogenomics and personalized medicine: a review focused on their application in the Chinese population. Acta Pharmacologica Sinica, 2015, 36, 535-543.	6.1	20
15	Development and validation of a sensitive LC–MS/MS method for determination of gefitinib and its major metabolites in human plasma and its application in non-small cell lung cancer patients. Journal of Pharmaceutical and Biomedical Analysis, 2019, 172, 364-371.	2.8	20
16	The Dissociation of Gefitinib Trough Concentration and Clinical Outcome in NSCLC Patients with EGFR Sensitive Mutations. Scientific Reports, 2015, 5, 12675.	3.3	17
17	Randomised clinical trial: dose optimising strategy by *NUDT15* genotyping reduces leucopenia during thiopurine treatment of Crohn's disease. Alimentary Pharmacology and Therapeutics, 2021, 54, 1124-1133.	3.7	15
18	Simultaneous quantification of imatinib and its main metabolite N–demethyl–imatinib in human plasma by liquid chromatography–tandem mass spectrometry and its application to therapeutic drug monitoring in patients with gastrointestinal stromal tumor. Biomedical Chromatography, 2017, 31, e4022.	1.7	13

#	Article	IF	Citations
19	Single Nucleotide Polymorphisms of the Pregnane X Receptor Gene in Han Chinese and a Comparison with Other Ethnic Populations. Pharmacology, 2008, 81, 350-354.	2.2	12
20	Correlation of MCT1 and ABCC2 gene polymorphisms with valproic acid resistance in patients with epilepsy on valproic acid monotherapy. Drug Metabolism and Pharmacokinetics, 2019, 34, 165-171.	2.2	12
21	Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients?. Cancer Medicine, 2018, 7, 317-324.	2.8	11
22	The analysis of pharmacokinetic and pharmacogenomic impact on gefitinib efficacy in advanced non-small cell lung cancer patients: results from a prospective cohort study. Annals of Translational Medicine, 2019, 7, 806-806.	1.7	11
23	Simultaneous and rapid quantitation of benazepril and benazeprilat in human plasma by high performance liquid chromatography with ultraviolet detection. Journal of Pharmaceutical and Biomedical Analysis, 2007, 44, 224-230.	2.8	10
24	A rapid and simple HPLCâ€"MS/MS method for the simultaneous quantification of valproic acid and its five metabolites in human plasma and application to study pharmacokinetic interaction in Chinese epilepsy patients. Journal of Pharmaceutical and Biomedical Analysis, 2018, 149, 448-456.	2.8	10
25	Establishment and application of a predictive model for gefitinib-induced severe rash based on pharmacometabolomic profiling and polymorphisms of transporters in non-small cell lung cancer. Translational Oncology, 2021, 14, 100951.	3.7	9
26	Impact of STAT1 polymorphisms on crizotinib-induced hepatotoxicity in ALK-positive non-small cell lung cancer patients. Journal of Cancer Research and Clinical Oncology, 2021, 147, 725-737.	2.5	9
27	Association of polymorphisms in C1orf106, IL1RN, and IL10 with post-induction infliximab trough level in Crohnâ€™s disease patients. Gastroenterology Report, 2020, 8, 367-373.	1.3	8
28	Polymorphisms of NF-κB pathway genes influence adverse drug reactions of gefitinib in NSCLC patients. Pharmacogenomics Journal, 2020, 20, 285-293.	2.0	6
29	Associations of HSD11B1 Polymorphisms with Tacrolimus Concentrations in Chinese Renal Transplant Recipients with Prednisone Combined Therapy. Drug Metabolism and Disposition, 2015, 43, 455-458.	3.3	5
30	Nucleoside diphosphate-linked moiety X-type motif 15 R139C genotypes impact 6-thioguanine nucleotide cut-off levels to predict thiopurine-induced leukopenia in Crohnâ€™s disease patients. World Journal of Gastroenterology, 2019, 25, 5850-5861.	3.3	5
31	Novel Clinical Biomarkers for Drug-Induced Liver Injury. Drug Metabolism and Disposition, 2022, 50, 671-684.	3.3	5
32	Diltiazem augments the influence of MDR1 genotype status on cyclosporine concentration in Chinese patients with renal transplantation. Acta Pharmacologica Sinica, 2015, 36, 855-862.	6.1	4
33	Low initial trough concentration of rituximab is associated with unsatisfactory response of first-line R-CHOP treatment in patients with follicular lymphoma with grade 1/2. Acta Pharmacologica Sinica, 2021, 42, 641-647.	6.1	4
34	FOXO3 mutation predicting gefitinib-induced hepatotoxicity in NSCLC patients through regulation of autophagy. Acta Pharmaceutica Sinica B, 2022, 12, 3639-3649.	12.0	4
35	LCâ€"MS/MS quantification of levetiracetam, lamotrigine and 10â€‘hydroxycarbazepine in TDM of epileptic patients. Biomedical Chromatography, 2022, 36, e5393.	1.7	4
36	Rituximab exposureâ€‘response in triweekly Râ€‘CHOP treatment in DLBCL: A loading dose is recommended to improve clinical outcomes. Clinical and Translational Science, 2022, 15, 680-690.	3.1	3

#	Article	IF	Citations
37	Xanthine oxidase activity in thiopurine curative Chinese inflammatory bowel disease patients. Pharmacology Research and Perspectives, 2021, 9, e00764.	2.4	2
38	A rapid and sensitive UHPLC–MS/MS method for quantification of 83b1 in plasma and its application to bioavailability study in rats. Journal of Pharmaceutical and Biomedical Analysis, 2017, 134, 71-76.	2.8	1
39	Rational application of gefitinib in NSCLC patients with sensitive EGFR mutations based on pharmacokinetics and metabolomics. Acta Pharmacologica Sinica, 2022, 43, 1857-1864.	6.1	1
40	Rituximab Concentration Varies in Patients With Different Lymphoma Subtypes and Correlates With Clinical Outcome. Frontiers in Pharmacology, 2022, 13, 788824.	3.5	1
41	STAT6 polymorphism was correlated with gefitinib-induced diarrhea in patients with non-small cell lung cancer.. Journal of Clinical Oncology, 2021, 39, e21046-e21046.	1.6	0
42	An integrative scoring system for survival prediction following gefitinib therapy in non-small cell lung cancer: From a long-term real-world study.. Journal of Clinical Oncology, 2021, 39, e21041-e21041.	1.6	0
43	Relation of the BIM deletion polymorphism to intrinsic EGFR-TKI resistance of Chinese patients with EGFR mutant advanced non-small cell lung cancer.. Journal of Clinical Oncology, 2016, 34, e14095-e14095.	1.6	0
44	Next generation sequencing (NGS) in wild type GISTs.. Journal of Clinical Oncology, 2017, 35, e22507-e22507.	1.6	0
45	A novel correlation between KIT promoter DNA methylation and prognostic of gastrointestinal stromal tumors.. Journal of Clinical Oncology, 2018, 36, e23514-e23514.	1.6	0
46	Relationship among ETV1 genetic polymorphisms, PFS, and microRNA in gastrointestinal stromal tumors.. Journal of Clinical Oncology, 2019, 37, e22513-e22513.	1.6	0
47	Correlation of gefitinib and its metabolites with gefitinib induced rash in patients with non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2020, 38, e21712-e21712.	1.6	0
48	Multi-alleles predict primary non-response to infliximab therapy in Crohn's disease. Gastroenterology Report, 2021, 9, 427-434.	1.3	0